Reviewed by Susha Cheriyedath, M.Sc. Jun 25 2025 A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment.

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.

In comparison, the average weight loss in the phase 3 clinical trials was 14.9% for once-weekly semaglutide 2.4 mg, 15.0% for tirzepatide 5 mg, and 20.9% for tirzepatide 15 mg.

Apitegromab therapy (10 mg/kg) with tirzepatide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tirzepatide alone, leading to higher quality weight loss.

By Hugo Francisco de Souza A new clinical trial reveals tirzepatide’s ability to curb hunger and alter brain responses to food, marking a new era in obesity treatment. Study: Tirzepatide on ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

The EMBRAZE trial was designed to assess the ability to preserve lean body mass associated with tirzepatide-induced weight loss in patients with obesity (BMI of ≥30.0 kg/m 2) or overweight (BMI ...

THURSDAY, June 12, 2025 (HealthDay News) -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower ...